Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ocugen, Inc. (OCGN)
USD1.43
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
263 Great Valley Parkway 19355
Malvern, PA, US
Malvern, PA, US
CEO
Shankar Musunuri
Website
ocugen.com
IPO
2014-12-03
CIK 1372299 ISIN US67577C1053
Description
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Stock Market LLC | HSGX | 2019-06-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.43
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
2.21
Float Shares
329.04M
Free Float %
97.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.68% | -2.00% | -17.88% | +4.26% | +18.55% | +8.89% | +109.25% | +100.27% | -82.14% | -98.70% | -99.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.43
Low
3.50
+144.8%
Consensus
5.00
+249.7%
Median
5.00
+249.7%
High
6.00
+319.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 5 |
5.00
+249.7%
|
Quality scores
Altman Z-Score
-8.12
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+8.8% ★ Q1'26: +3.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-15.0% Q1'26: -13.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,505.2% Q1'26: -1,422.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,425.7% Q1'26: -1,164.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-2,613.9% Q1'26: -985.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+10.8% Q1'26: +9.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.55× Q1'26: -0.48× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 5 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 91.97M (-100.0%)
|
2.49M
est: 2.17M (+14.8%)
|
6.04M
est: 7.26M (-16.9%)
|
4.06M
est: 3.62M (+11.9%)
|
4.41M
est: 5.60M (-21.2%)
|
3.51M
3.05M – 3.74M
-37.4% YoY
|
10.22M
3.60M – 21.24M
+191.2% YoY
|
205.72M
202.62M – 208.82M
+1,913.2% YoY
|
590.88M
284.23M – 1.08B
+187.2% YoY
|
1.23B
591.97M – 2.25B
+108.3% YoY
|
| EBITDA |
-57.80M
est: -87.66M (+34.1%)
|
-88.59M
est: -1.30M (-6,714.7%)
|
-64.83M
est: -4.36M (-1,387.6%)
|
-52.79M
est: -2.17M (-2,328.6%)
|
-60.53M
est: -3.36M (-1,700.9%)
|
-2.11M
-2.24M – -1.83M
+37.4% YoY
|
-6.13M
-12.75M – -2.16M
-191.2% YoY
|
-123.43M
-125.29M – -121.57M
-1,913.2% YoY
|
-354.53M
-647.73M – -170.54M
-187.2% YoY
|
-738.38M
-1.35B – -355.18M
-108.3% YoY
|
| EBIT |
-58.03M
est: -87.23M (+33.5%)
|
-89.07M
est: -1.30M (-6,751.6%)
|
-65.53M
est: -4.36M (-1,403.8%)
|
-54.76M
est: -2.17M (-2,419.1%)
|
-62.92M
est: -3.36M (-1,772.0%)
|
-2.11M
-2.24M – -1.83M
+37.4% YoY
|
-6.13M
-12.75M – -2.16M
-191.2% YoY
|
-123.43M
-125.29M – -121.57M
-1,913.2% YoY
|
-354.53M
-647.73M – -170.54M
-187.2% YoY
|
-738.38M
-1.35B – -355.18M
-108.3% YoY
|
| Net Income |
-58.37M
est: -87.96M (+33.6%)
|
-86.80M
est: -102.37M (+15.2%)
|
-63.08M
est: -44.90M (-40.5%)
|
-54.05M
est: -56.99M (+5.1%)
|
-67.85M
est: -71.67M (+5.3%)
|
-64.75M
-71.22M – -58.27M
+9.7% YoY
|
6.67M
5.85M – 7.48M
+110.3% YoY
|
34.23M
-190.69M – 395.69M
+413.5% YoY
|
247.64M
80.57M – 513.88M
+623.4% YoY
|
543.30M
176.75M – 1.13B
+119.4% YoY
|
| SGA |
22.92M
est: 31.63M (-27.5%)
|
35.40M
est: 92.11M (-61.6%)
|
31.99M
est: 48.46M (-34.0%)
|
26.69M
est: 24.17M (+10.4%)
|
27.58M
est: 37.37M (-26.2%)
|
23.41M
20.38M – 24.95M
-37.4% YoY
|
68.18M
24.02M – 141.72M
+191.2% YoY
|
1.37B
1.35B – 1.39B
+1,913.2% YoY
|
3.94B
1.90B – 7.20B
+187.2% YoY
|
8.21B
3.95B – 15.00B
+108.3% YoY
|
| EPS |
-0.30
est: -0.30 (-1.7%)
|
-0.40
est: -0.38 (-5.3%)
|
-0.26
est: -0.17 (-48.8%)
|
-0.20
est: -0.20 (+0.0%)
|
-0.23
est: -0.23 (-0.5%)
|
-0.22
-0.24 – -0.19
+5.7% YoY
|
0.02
0.02 – 0.02
+110.0% YoY
|
0.14
-0.64 – 1.32
+523.1% YoY
|
0.83
0.27 – 1.71
+511.1% YoY
|
1.81
0.59 – 3.76
+119.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-55.96M
OE per share TTM
-0.19
Owner's Yield
-11.96%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
331.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
1.04M
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SSGA FUNDS MANAGEMENT, INC. | 25.21M | 11.73% | — | 25.16M | — | 25.21M | IA | BOSTON, MASSACHUSETTS | 2022-04-11 | ↗ |
| 2 | (1) BlackRock, Inc. | 18.61M | 6.50% | 18.46M | — | 18.61M | — | HC | Delaware | 2024-11-08 | ↗ |
| 3 | STATE STREET CORPORATION | 15.82M | 5.50% | — | 15.39M | — | — | HC | MA | 2024-10-16 | ↗ |
| 4 | The Vanguard Group - 23-1945930 | 10.61M | 5.32% | — | 352.7K | 10.10M | 509.5K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 5 | Empery Debt Opportunity Fund, LP | 7.05M | 9.49% | — | 7.05M | — | — | PN | Delaware | 2020-04-24 | ↗ |
| 6 | Hudson Bay Capital Management LP | 3.46M | 5.29% | — | 3.46M | — | — | PN | State of Delaware | 2019-02-04 | ↗ |
| 7 | Sander Gerber | 3.46M | 5.29% | — | 3.46M | — | — | IN | State of Delaware | 2019-02-04 | ↗ |
| 8 | Intrexon Corporation | 2.69M | 21.10% | — | — | — | 10.00 | CO | Virginia | 2014-12-10 | ↗ |
| 9 | Randal J. Kirk | 2.69M | 21.10% | — | — | — | 10.00 | IN | United States | 2014-12-10 | ↗ |
| 10 | 10 | 2.20M | 8.80% | — | — | — | 2.20M | IA | Delaware | 2018-01-26 | ↗ |
| 11 | Sofinnova Management VIII, L.L.C. (“SM VIII”) | 2.08M | 16.30% | 2.08M | 2.08M | 2.08M | — | OO | Delaware | 2015-02-17 | ↗ |
| 12 | Sofinnova Venture Partners VIII, L.P. (“SVP VIII”) | 2.08M | 16.30% | 2.08M | 2.08M | 2.08M | 2.08M | PN | Delaware | 2015-02-17 | ↗ |
| 13 | S | 2.08M | 15.60% | 2.08M | 2.08M | 2.08M | — | OO | Delaware | 2016-02-11 | ↗ |
| 14 | Abigail P. Johnson | 1.88M | 14.70% | — | — | 1.88M | — | IN | Delaware | 2015-01-12 | ↗ |
| 15 | Edward C. Johnson 3d | 1.88M | 14.70% | — | — | 1.88M | — | IN | Delaware | 2015-01-12 | ↗ |
| 16 | Split Rock Partners II Management, LLC | 1.38M | 10.90% | 1.38M | — | 1.38M | 10.00 | OO | Delaware | 2014-12-12 | ↗ |
| 17 | Split Rock Partners II, LP | 1.38M | 10.90% | 1.38M | — | 1.38M | 10.00 | PN | Delaware | 2014-12-12 | ↗ |
| 18 | Armistice Capital Master Fund Ltd. | 1.33M | 2.10% | — | 1.33M | — | 1.33M | CO | Delaware | 2019-02-14 | ↗ |
| 19 | Armistice Capital, LLC | 1.33M | 2.10% | — | 1.33M | — | 1.33M | IA, OO | Delaware | 2019-02-14 | ↗ |
| 20 | Steven Boyd | 1.33M | 2.10% | — | 1.33M | — | 1.33M | HC, IN | Delaware | 2019-02-14 | ↗ |
| 21 | Select Biotechnology Portfolio | 1.24M | 9.73% | 1.24M | — | — | — | IV | Delaware | 2015-01-12 | ↗ |
| 22 | Empery Asset Management, LP | — | 0.00% | — | — | — | — | PN | Delaware | 2021-01-26 | ↗ |
| 23 | FMR LLC | — | 0.00% | — | — | — | — | HC | United States of America | 2018-10-10 | ↗ |
| 24 | Martin D. Hoe | — | 0.00% | — | — | — | — | IN | Delaware | 2021-01-26 | ↗ |
| 25 | Ryan M. Lane | — | 0.00% | — | — | — | — | IN | Delaware | 2021-01-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-89 vs prev Q
New positions
7
Closed positions
90
Increased
10
Reduced
3
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 16.48M +1.3M (+8.2%) | 22.24M -2.6M (-10.4%) | 5.42% +0.207 pp | 0.00% +0.000 pp | USD1.95 -30.8% | 26 qtrs — |
| 2 | MILLENNIUM MANAGEMENT LLC | 5.40M +1.2M (+29.7%) | 7.29M +500.9K (+7.4%) | 1.78% +0.350 pp | 0.00% +0.000 pp | USD1.06 +27.4% | 5 qtrs — |
| 3 | UBS GROUP AG | 4.85M +3.8M (+373.2%) | 6.55M +4.9M (+291.9%) | 1.60% +1.244 pp | 0.00% +0.001 pp | USD1.30 +3.8% | 24 qtrs — |
| 4 | BLACKROCK, INC. | 4.56M +502.1K (+12.4%) | 6.15M -457.4K (-6.9%) | 1.50% +0.111 pp | 0.00% +0.000 pp | USD1.02 +32.4% | 6 qtrs — |
| 5 | STATE STREET CORP | 3.98M +2.6M (+193.6%) | 5.37M +3.2M (+143.1%) | 1.31% +0.845 pp | 0.00% +0.000 pp | USD1.48 -8.8% | 21 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 3.82M +142.1K (+3.9%) | 5.16M -837.3K (-14.0%) | 1.26% -0.003 pp | 0.00% 0.000 pp | USD2.37 -43.0% | 24 qtrs — |
| 7 | MARSHALL WACE, LLP | 2.53M +2.5M (+100.0%) | 3.42M +3.4M (+100.0%) | 0.83% +0.833 pp | 0.00% +0.003 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 8 | GOLDMAN SACHS GROUP INC | 2.30M +2.2M (+2,256.4%) | 3.11M +2.9M (+1,851.7%) | 0.76% +0.724 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 8 qtrs — |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 1.70M +1.4M (+485.9%) | 2.30M +1.8M (+385.3%) | 0.56% +0.460 pp | 0.00% +0.003 pp | USD1.40 -3.6% | 5 qtrs — |
| 10 | JANE STREET GROUP, LLC | 1.69M +816.5K (+93.3%) | 2.28M +857.2K (+60.1%) | 0.56% +0.257 pp | 0.00% +0.000 pp | USD1.15 +17.4% | 21 qtrs — |
| 11 | HENNION & WALSH ASSET MANAGEMENT, INC. | 1.01M +1.0M (+100.0%) | 1.36M +1.4M (+100.0%) | 0.33% +0.331 pp | 0.05% +0.047 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 12 | RINKEY INVESTMENTS | 991.2K -121.5K (-10.9%) | 1.34M -475.6K (-26.2%) | 0.33% -0.055 pp | 0.34% -0.141 pp | USD0.71 +90.1% | 4 qtrs — |
| 13 | CI PRIVATE WEALTH, LLC | 900.0K +— (+0.0%) | 1.22M -252.0K (-17.2%) | 0.30% -0.012 pp | 0.00% -0.001 pp | USD1.63 -17.2% | 7 qtrs — |
| 14 | GSA CAPITAL PARTNERS LLP | 885.1K -156.5K (-15.0%) | 1.20M -503.0K (-29.6%) | 0.29% -0.066 pp | 0.10% -0.039 pp | USD0.81 +66.7% | 6 qtrs — |
| 15 | TWO SIGMA INVESTMENTS, LP | 678.5K +605.5K (+828.4%) | 916.0K +796.9K (+668.9%) | 0.22% +0.198 pp | 0.00% +0.001 pp | USD1.38 -2.2% | 2 qtrs — |
| 16 | NORTHERN TRUST CORP | 666.2K +69.7K (+11.7%) | 899.4K -73.0K (-7.5%) | 0.22% +0.015 pp | 0.00% +0.000 pp | USD1.78 -24.2% | 24 qtrs — |
| 17 | MORGAN STANLEY | 463.5K +172.9K (+59.5%) | 625.7K +152.0K (+32.1%) | 0.15% +0.053 pp | 0.00% +0.000 pp | USD1.79 -24.6% | 23 qtrs — |
| 18 | POINT72 ASSET MANAGEMENT, L.P. | 426.3K +426.3K (+100.0%) | 575.5K +575.5K (+100.0%) | 0.14% +0.140 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 19 | XTX TOPCO LTD | 352.1K -103.2K (-22.7%) | 475.4K -266.8K (-35.9%) | 0.12% -0.040 pp | 0.01% -0.026 pp | USD1.33 +1.5% | 6 qtrs — |
| 20 | OMERS ADMINISTRATION CORP | 331.3K +331.3K (+100.0%) | 447.3K +447.3K (+100.0%) | 0.11% +0.109 pp | 0.00% +0.003 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 21 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 268.1K -55.3K (-17.1%) | 361.9K -165.2K (-31.3%) | 0.09% -0.023 pp | 0.00% +0.000 pp | USD1.52 -11.2% | 20 qtrs — |
| 22 | TWO SIGMA ADVISERS, LP | 267.5K +267.5K (+100.0%) | 361.1K +361.1K (+100.0%) | 0.09% +0.088 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 23 | CITADEL ADVISORS LLC | 224.5K +68.2K (+43.6%) | 303.1K +48.3K (+19.0%) | 0.07% +0.020 pp | 0.00% +0.000 pp | USD1.54 -12.3% | 20 qtrs — |
| 24 | PROCYON ADVISORS, LLC | 224.1K +13.0K (+6.2%) | 302.5K -41.6K (-12.1%) | 0.07% +0.001 pp | 0.01% -0.005 pp | USD1.02 +32.4% | 3 qtrs — |
| 25 | SQUAREPOINT OPS LLC | 218.4K +175.4K (+408.3%) | 294.8K +224.8K (+321.0%) | 0.07% +0.057 pp | 0.00% +0.000 pp | USD1.41 -4.3% | 5 qtrs — |
| 26 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 209.2K +209.2K (+100.0%) | 288.7K +288.7K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 27 | CANADA PENSION PLAN INVESTMENT BOARD | 192.9K +192.9K (+100.0%) | 260.4K +260.4K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 171.7K +— (+0.0%) | 231.8K -48.1K (-17.2%) | 0.06% -0.002 pp | 0.00% +0.000 pp | USD2.51 -46.2% | 20 qtrs — |
| 29 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 171.0K +171.0K (+100.0%) | 230.9K +230.9K (+100.0%) | 0.06% +0.056 pp | 0.01% +0.007 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 30 | BARCLAYS PLC | 157.5K -423.6K (-72.9%) | 212.6K -363.9K (-63.1%) | 0.05% -0.147 pp | 0.00% 0.000 pp | USD1.60 -15.6% | 7 qtrs — |
| 31 | FMR LLC | 150.8K -877.0 (-0.6%) | 203.6K -43.7K (-17.7%) | 0.05% -0.002 pp | 0.00% +0.000 pp | USD0.70 +92.9% | 17 qtrs — |
| 32 | BALYASNY ASSET MANAGEMENT L.P. | 145.4K +145.4K (+100.0%) | 196.3K +196.3K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 33 | QUADRATURE CAPITAL LTD | 143.9K -307.7K (-68.1%) | 194.3K -539.5K (-73.5%) | 0.05% -0.107 pp | 0.00% -0.007 pp | USD1.63 -17.2% | 2 qtrs — |
| 34 | NEWEDGE ADVISORS, LLC | 135.5K +55.3K (+69.0%) | 182.9K +52.2K (+40.0%) | 0.04% +0.017 pp | 0.00% +0.000 pp | USD1.31 +3.1% | 10 qtrs — |
| 35 | TWO SIGMA SECURITIES, LLC | 134.9K +67.0K (+98.7%) | 182.1K +71.5K (+64.6%) | 0.04% +0.021 pp | 0.03% +0.009 pp | USD1.31 +3.1% | 17 qtrs — |
| 36 | GROUP ONE TRADING, L.P. | 118.3K +50.2K (+73.7%) | 159.7K +48.7K (+43.9%) | 0.04% +0.016 pp | 0.00% +0.000 pp | USD1.15 +17.4% | 17 qtrs — |
| 37 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 115.0K +115.0K (+100.0%) | 155.2K +155.2K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 3 qtrs — |
| 38 | JAIN GLOBAL LLC | 114.7K +7.7K (+7.2%) | 154.8K -19.6K (-11.2%) | 0.04% +0.001 pp | 0.00% 0.000 pp | USD1.00 +35.0% | 3 qtrs — |
| 39 | JEFFERIES FINANCIAL GROUP INC. | 101.9K -5.4K (-5.0%) | 137.6K -37.3K (-21.3%) | 0.03% -0.003 pp | 0.00% 0.000 pp | USD1.63 -17.2% | 2 qtrs — |
| 40 | CITIGROUP INC | 101.9K +101.6K (+44,194.8%) | 137.5K +137.2K (+36,576.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 20 qtrs — |
| 41 | LANHAM O'DELL & COMPANY, INC. | 100.0K -40.0K (-28.6%) | 135.0K -93.2K (-40.8%) | 0.03% -0.015 pp | 0.04% -0.034 pp | USD0.80 +68.8% | 4 qtrs — |
| 42 | BANK OF AMERICA CORP /DE/ | 98.7K -55.7K (-36.1%) | 133.2K -118.4K (-47.1%) | 0.03% -0.020 pp | 0.00% +0.000 pp | USD1.59 -15.1% | 20 qtrs — |
| 43 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 82.3K +82.2K (+76,831.8%) | 111.1K +111.0K (+63,766.7%) | 0.03% +0.027 pp | 0.03% +0.027 pp | USD1.35 +0.0% | 2 qtrs — |
| 44 | VIRTU FINANCIAL LLC | 78.2K +78.2K (+100.0%) | 106.0K +106.0K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.004 pp | USD1.35 +0.0% | 5 qtrs — |
| 45 | SIMPLEX TRADING, LLC | 72.4K +64.2K (+782.5%) | 97.7K +84.7K (+651.7%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD1.31 +3.1% | 12 qtrs — |
| 46 | HEADLANDS TECHNOLOGIES LLC | 70.7K +4.6K (+6.9%) | 95.5K -12.4K (-11.5%) | 0.02% +0.001 pp | 0.01% -0.001 pp | USD1.61 -16.1% | 2 qtrs — |
| 47 | TOWER RESEARCH CAPITAL LLC (TRC) | 61.8K +61.7K (+176,394.3%) | 83.4K +83.3K (+146,205.3%) | 0.02% +0.020 pp | 0.00% +0.002 pp | USD1.35 +0.0% | 21 qtrs — |
| 48 | CAPTRUST FINANCIAL ADVISORS | 60.0K -2.0 (0.0%) | 81.0K -16.8K (-17.2%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD0.45 +200.0% | 11 qtrs — |
| 49 | OPPENHEIMER & CO INC | 43.8K +— (+0.0%) | 59.1K -12.3K (-17.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.51 -10.6% | 7 qtrs — |
| 50 | STATE OF WYOMING | 42.8K +42.8K (+100.0%) | 57.7K +57.7K (+100.0%) | 0.01% +0.014 pp | 0.01% +0.006 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 51 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 40.0K +— (+0.0%) | 54.0K -11.2K (-17.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD0.71 +90.1% | 4 qtrs — |
| 52 | BANK OF NEW YORK MELLON CORP | 37.1K +— (+0.0%) | 50.0K -10.4K (-17.2%) | 0.01% -0.001 pp | 0.00% +0.000 pp | USD1.68 -19.6% | 21 qtrs — |
| 53 | VICTORY CAPITAL MANAGEMENT INC | 35.4K +114.0 (+0.3%) | 47.8K -9.7K (-16.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.57 -14.0% | 7 qtrs — |
| 54 | VERDENCE CAPITAL ADVISORS LLC | 33.0K +3.0K (+10.0%) | 44.6K -2.3K (-4.8%) | 0.01% +0.001 pp | 0.00% 0.000 pp | USD1.60 -15.6% | 2 qtrs — |
| 55 | ETHIC INC. | 31.6K -31.0 (-0.1%) | 42.6K -8.9K (-17.3%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD0.97 +39.2% | 3 qtrs — |
| 56 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 30.3K +450.0 (+1.5%) | 40.9K -7.8K (-15.9%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD0.65 +107.7% | 11 qtrs — |
| 57 | CORA CAPITAL ADVISORS LLC | 30.1K +6.5K (+27.5%) | 40.7K +2.2K (+5.6%) | 0.01% +0.002 pp | 0.02% -0.001 pp | USD1.47 -8.2% | 7 qtrs — |
| 58 | DIVERSIFY WEALTH MANAGEMENT, LLC | 20.0K +— (+0.0%) | 38.2K +7.4K (+24.0%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.63 -17.2% | 7 qtrs — |
| 59 | ADVISOR GROUP HOLDINGS, INC. | 28.0K +22.0K (+366.8%) | 37.8K +31.3K (+477.3%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD1.39 -2.9% | 21 qtrs — |
| 60 | SCHONFELD STRATEGIC ADVISORS LLC | 27.9K +27.9K (+100.0%) | 37.7K +37.7K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 3 qtrs — |
| 61 | BALDWIN INVESTMENT MANAGEMENT, LLC | 25.0K +— (+0.0%) | 33.8K -7.0K (-17.2%) | 0.01% 0.000 pp | 0.00% -0.001 pp | USD0.97 +39.2% | 3 qtrs — |
| 62 | SBI SECURITIES CO., LTD. | 24.1K -77.0 (-0.3%) | 32.5K -6.9K (-17.4%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD0.80 +68.8% | 5 qtrs — |
| 63 | — | 22.7K +22.7K (+100.0%) | 30.6K +30.6K (+100.0%) | 0.01% +0.008 pp | 0.01% +0.011 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 64 | MARINER, LLC | 22.3K -38.0 (-0.2%) | 30.1K -6.3K (-17.3%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD0.75 +80.0% | 4 qtrs — |
| 65 | CREATIVE PLANNING | 22.0K +3.3K (+17.5%) | 29.6K -809.0 (-2.7%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD1.03 +31.1% | 3 qtrs — |
| 66 | TRUEFG, LLC | 21.0K +— (+0.0%) | 28.4K -5.9K (-17.2%) | 0.01% 0.000 pp | 0.01% -0.002 pp | USD1.54 -12.3% | 8 qtrs — |
| 67 | LEVEL FOUR ADVISORY SERVICES, LLC | 19.0K +— (+0.0%) | 25.7K -5.3K (-17.2%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD0.71 +90.1% | 4 qtrs — |
| 68 | BLUESHIFT ASSET MANAGEMENT, LLC | 18.7K +18.7K (+100.0%) | 25.2K +25.2K (+100.0%) | 0.01% +0.006 pp | 0.01% +0.007 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 69 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 15.6K -119.0 (-0.8%) | 24.0K -3.6K (-13.2%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.52 -11.2% | 7 qtrs — |
| 70 | WEDMONT PRIVATE CAPITAL | 14.8K +— (+0.0%) | 23.5K -2.5K (-9.7%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD0.57 +136.8% | 9 qtrs — |
| 71 | KOVACK ADVISORS, INC. | 17.3K +17.3K (+100.0%) | 23.4K +23.4K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.001 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 72 | BNP PARIBAS ARBITRAGE, SNC | 16.4K +12.0K (+272.1%) | 22.1K +15.0K (+208.2%) | 0.01% +0.004 pp | 0.00% +0.000 pp | USD1.22 +10.7% | 5 qtrs — |
| 73 | AMERIPRISE FINANCIAL INC | 15.6K +15.6K (+100.0%) | 21.0K +21.0K (+100.0%) | 0.01% +0.005 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 74 | PERENNIAL INVESTMENT ADVISORS, LLC | 15.0K +— (+0.0%) | 20.3K -4.2K (-17.2%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD1.30 +3.8% | 13 qtrs — |
| 75 | ABEL HALL, LLC | 14.8K +— (+0.0%) | 20.0K -4.1K (-17.2%) | 0.00% 0.000 pp | 0.00% -0.005 pp | USD0.76 +77.6% | 4 qtrs — |
| 76 | LPL FINANCIAL LLC | 14.1K +14.1K (+100.0%) | 19.1K +19.1K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 3 qtrs — |
| 77 | TUDOR INVESTMENT CORP ET AL | 13.7K +— (+0.0%) | 18.5K -3.8K (-17.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.99 +36.4% | 13 qtrs — |
| 78 | ALPINE GLOBAL MANAGEMENT, LLC | 13.4K +13.4K (+100.0%) | 18.1K +18.1K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.003 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 79 | R SQUARED LTD | 13.2K +13.2K (+100.0%) | 17.8K +17.8K (+100.0%) | 0.00% +0.004 pp | 0.01% +0.008 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 80 | PENSIONMARK FINANCIAL GROUP, LLC | 12.0K +12.0K (+100.0%) | 16.2K +16.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 81 | CETERA INVESTMENT ADVISERS | 10.0K +10.0K (+100.0%) | 13.5K +13.5K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 82 | UNITING WEALTH PARTNERS, LLC | 10.0K +— (+0.0%) | 13.5K -2.8K (-17.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.63 -17.2% | 2 qtrs — |
| 83 | HARBOUR INVESTMENTS, INC. | 6.7K +— (+0.0%) | 9.1K -1.9K (-17.2%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD0.85 +58.8% | 13 qtrs — |
| 84 | PNC FINANCIAL SERVICES GROUP, INC. | 5.2K +— (+0.0%) | 7.1K -1.5K (-17.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.83 +62.7% | 5 qtrs — |
| 85 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 5.0K +— (+0.0%) | 6.7K -1.4K (-17.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.71 +90.1% | 4 qtrs — |
| 86 | ROYAL BANK OF CANADA | 4.0K -334.9K (-98.8%) | 6.0K -547.0K (-98.9%) | 0.00% -0.115 pp | 0.00% 0.000 pp | USD0.98 +37.8% | 20 qtrs — |
| 87 | WELLS FARGO & COMPANY/MN | 4.0K +2.9K (+273.9%) | 5.4K +3.7K (+209.7%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.33 +1.5% | 21 qtrs — |
| 88 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 3.0K +3.0K (+100.0%) | 4.1K +4.1K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.35 +0.0% | 1 qtrs NEW |
| 89 | CWM, LLC | 2.5K -112.0 (-4.3%) | 3.0K -1.0K (-25.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.37 -1.5% | 17 qtrs — |
| 90 | WEALTHCOLLAB, LLC | 1.7K +— (+0.0%) | 2.3K -476.0 (-17.2%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD0.71 +90.1% | 4 qtrs — |
| 91 | NISA INVESTMENT ADVISORS, LLC | 1.5K +— (+0.0%) | 2.0K -422.0 (-17.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.97 +39.2% | 6 qtrs — |
| 92 | EVERSOURCE WEALTH ADVISORS, LLC | 1.3K +— (+0.0%) | 1.7K -350.0 (-17.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.50 +170.0% | 10 qtrs — |
| 93 | GENEOS WEALTH MANAGEMENT INC. | 1.1K +— (+0.0%) | 1.5K -313.0 (-17.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.63 -17.2% | 7 qtrs — |
| 94 | RONALD BLUE TRUST, INC. | 1.0K +— (+0.0%) | 1.4K -280.0 (-17.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.25 +8.0% | 8 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 55 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.54% | 1.06M | 0.47% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.19% | 68.6K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.19% | 20.62M | 0.35% |
| 4 | iShares Micro-Cap ETF IWC | 0.11% | 1.69M | 0.60% |
| 5 | State Street SPDR S&P Kensho New Economies Composite ETF KOMP | 0.10% | 2.67M | 0.20% |
| 6 | Goldman Sachs Innovate Equity ETF GINN | 0.04% | 93.2K | 0.50% |
| 7 | iShares Ageing Population UCITS ETF AGED.L | 0.04% | 378.8K | 0.40% |
| 8 | Pacer WealthShield ETF PWS | 0.04% | 9.6K | 0.60% |
| 9 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.02% | 160.4K | 0.96% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.26M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
3
Sells
3
Shares acquired
194.1K
Shares disposed
194.1K
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Zhang Junge | Director | M-Exempt | A | Common Stock | 66,929 | 1.42 | 95.0K | 1,359,316 | D | ↗ |
| 2026-03-04 | Johnson-Greene Treerita Essalima | Officer | — | — | Common Stock | 0 | 0.00 | — | 350 | I | ↗ |
| 2026-01-02 | Ramachandran Ramesh | Officer | A-Award | A | Option (Right to Buy) | 310,950 | 1.38 | 429.1K | 310,950 | D | ↗ |
| 2026-01-02 | Musunuri Shankar | Director / Officer | A-Award | A | Common Stock | 3,123,201 | 0.00 | — | 4,955,924 | D | ↗ |
| 2025-06-05 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 151,316 | 0.95 | 143.8K | 151,316 | D | ↗ |
| 2025-06-05 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 151,316 | 0.95 | 143.8K | 151,316 | D | ↗ |
| 2025-06-05 | Coleman Blaise | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-05 | Chandrasekhar Satishchandran | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-05 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 151,316 | 0.95 | 143.8K | 151,316 | D | ↗ |
| 2025-01-03 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 41,633 | 0.89 | 37.2K | 306,197 | D | ↗ |
| 2025-01-03 | Musunuri Shankar | Director / Officer | F-InKind | D | Common Stock | 177,146 | 0.89 | 158.5K | 1,832,723 | D | ↗ |
| 2025-01-02 | Upadhyay Arun | Officer | A-Award | A | Option (Right to Buy) | 730,994 | 0.90 | 657.9K | 730,994 | D | ↗ |
| 2025-01-02 | Ramachandran Ramesh | Officer | A-Award | A | Option (Right to Buy) | 350,146 | 0.90 | 315.1K | 350,146 | D | ↗ |
| 2025-01-02 | Qamar Huma | Officer | A-Award | A | Option (Right to Buy) | 1,145,468 | 0.90 | 1.03M | 1,145,468 | D | ↗ |
| 2025-01-02 | Musunuri Shankar | Director / Officer | A-Award | A | Option (Right to Buy) | 1,827,485 | 0.90 | 1.64M | 1,827,485 | D | ↗ |
| 2024-11-26 | Fernandes Prabhavathi | Director | P-Purchase | A | Common Stock | 10,000 | 0.91 | 9.1K | 10,000 | D | ↗ |
| 2024-11-22 | Castillo Kirsten | Director | P-Purchase | A | Common Stock | 25,000 | 0.91 | 22.8K | 75,000 | D | ↗ |
| 2024-11-14 | Ramachandran Ramesh | Officer | — | — | Option (Right to Buy) | 154,596 | 1.25 | 193.2K | 0 | D | ↗ |
| 2024-09-16 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 842 | 1.17 | 985.14 | 347,830 | D | ↗ |
| 2024-06-28 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 66,929 | 1.55 | 103.7K | 66,929 | — | ↗ |
| 2024-06-28 | WHITTINGTON MARNA C | Director | A-Award | A | Option (Right to Buy) | 66,929 | 1.55 | 103.7K | 66,929 | — | ↗ |
| 2024-06-28 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 66,929 | 1.55 | 103.7K | 66,929 | — | ↗ |
| 2024-06-28 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 66,929 | 1.55 | 103.7K | 66,929 | — | ↗ |
| 2024-06-28 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 66,929 | 1.55 | 103.7K | 66,929 | — | ↗ |
| 2024-06-17 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 917 | 1.42 | 1.3K | 348,672 | — | ↗ |
| 2024-04-16 | Qamar Huma | Officer | A-Award | A | Option (Right to Buy) | 308,465 | 1.59 | 490.5K | 308,465 | — | ↗ |
| 2024-03-18 | Qamar Huma | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,643 | — | ↗ |
| 2024-01-03 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 41,633 | 0.65 | 27.2K | 349,589 | — | ↗ |
| 2024-01-03 | Musunuri Shankar | Director / Officer | F-InKind | D | Common Stock | 180,204 | 0.65 | 117.7K | 2,009,869 | — | ↗ |
| 2024-01-02 | Upadhyay Arun | Officer | A-Award | A | Option (Right to Buy) | 137,795 | 0.66 | 90.6K | 137,795 | — | ↗ |
| 2024-01-02 | Musunuri Shankar | Director / Officer | A-Award | A | Option (Right to Buy) | 492,126 | 0.66 | 323.6K | 492,126 | — | ↗ |
| 2023-09-16 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 842 | 0.41 | 345.22 | 391,222 | — | ↗ |
| 2023-09-15 | Breininger Michael | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-16 | Upadhyay Arun | Officer | F-InKind | D | Common Stock | 917 | 0.51 | 467.67 | 392,064 | — | ↗ |
| 2023-06-14 | Zhang Junge | Director | P-Purchase | A | Common Stock | 200,278 | 0.50 | 100.0K | 1,077,182 | — | ↗ |
| 2023-06-09 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-06-09 | WHITTINGTON MARNA C | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-06-09 | Kumar Ramesh | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-06-09 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-06-09 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-06-09 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 112,205 | 0.46 | 51.4K | 112,205 | — | ↗ |
| 2023-03-06 | Vu Quan Anh | Officer | — | D | Common Stock | 0 | 0.00 | — | 165,934 | — | ↗ |
| 2023-02-16 | Musunuri Shankar | Director / Officer | S-Sale | D | Common Stock | 100,000 | 1.08 | 108.0K | 2,190,073 | — | ↗ |
| 2023-01-17 | Musunuri Shankar | Officer | S-Sale | D | Common Stock | 100,000 | 1.28 | 128.0K | 2,227,950 | — | ↗ |
| 2023-01-03 | Upadhyay Arun | Officer | A-Award | A | Option (Right to Buy) | 379,357 | 0.00 | — | 379,357 | — | ↗ |
| 2023-01-03 | Musunuri Shankar | Officer | A-Award | A | Common Stock | 1,475,410 | 0.00 | — | 2,227,950 | — | ↗ |
| 2023-01-03 | Crespo Jessica | Officer | A-Award | A | Option (Right to Buy) | 147,638 | 0.00 | — | 147,638 | — | ↗ |
| 2023-01-01 | Upadhyay Arun | Officer | — | D | Option (Right to Buy) | 33,818 | 2.17 | 73.4K | — | — | ↗ |
| 2022-12-16 | Musunuri Shankar | Officer | M-Exempt | A | Common Stock | 95,809 | 0.51 | 48.9K | 848,349 | — | ↗ |
| 2022-10-14 | Musunuri Shankar | Officer | M-Exempt | A | Common Stock | 100,000 | 0.51 | 51.0K | 852,540 | — | ↗ |
| 2022-10-06 | Kumar Ramesh | Director | M-Exempt | A | Common Stock | 4,500 | 0.51 | 2.3K | 4,500 | — | ↗ |
| 2022-08-11 | Castillo Kirsten | Director | M-Exempt | A | Common Stock | 42,000 | 0.28 | 11.8K | 92,000 | — | ↗ |
| 2022-07-18 | Kumar Ramesh | Director | S-Sale | D | Common Stock | 7,500 | 2.57 | 19.3K | 0 | — | ↗ |
| 2022-07-14 | Musunuri Shankar | Director / Officer | M-Exempt | A | Common Stock | 150,000 | 0.33 | 49.5K | 902,540 | — | ↗ |
| 2022-06-07 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 140,091 | 0.00 | — | 140,091 | — | ↗ |
| 2022-06-07 | WHITTINGTON MARNA C | Director | A-Award | A | Option (Right to Buy) | 140,091 | 2.49 | 348.8K | 140,091 | — | ↗ |
| 2022-06-07 | Kumar Ramesh | Director | A-Award | A | Option (Right to Buy) | 140,091 | 0.00 | — | 140,091 | — | ↗ |
| 2022-06-07 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 140,091 | 2.49 | 348.8K | 140,091 | — | ↗ |
| 2022-06-07 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 140,091 | 0.00 | — | 140,091 | — | ↗ |
| 2022-06-07 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 140,091 | 0.00 | — | 140,091 | — | ↗ |
| 2022-05-13 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 125,000 | 0.33 | 41.3K | 779,764 | — | ↗ |
| 2022-04-18 | Kumar Ramesh | Director | S-Sale | D | Common Stock | 7,500 | 2.83 | 21.2K | 0 | — | ↗ |
| 2022-03-21 | WHITTINGTON MARNA C | Director | A-Award | A | Option (Right to Buy) | 106,383 | 3.72 | 395.7K | 106,383 | — | ↗ |
| 2022-03-18 | Crespo Jessica | Officer | A-Award | A | Option (Right to Buy) | 84,192 | 0.00 | — | 84,192 | — | ↗ |
| 2022-03-16 | Musunuri Shankar | Officer | M-Exempt | D | Option (Right to Buy) | 81,823 | 0.00 | — | 904,764 | — | ↗ |
| 2022-03-03 | Zhang Junge | Director | M-Exempt | A | Option (Right to Buy) | 39,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-02-14 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 90,000 | 0.33 | 29.7K | 986,587 | — | ↗ |
| 2022-01-18 | Kumar Ramesh | Director | M-Exempt | A | Option (Right to Buy) | 7,500 | 0.51 | 3.8K | 24,000 | — | ↗ |
| 2022-01-03 | Subramanian Sanjay | Officer | A-Award | A | Stock Option (Right to Buy) | 454,007 | 4.72 | 2.14M | 454,007 | — | ↗ |
| 2022-01-03 | Musunuri Shankar | Director / Officer | A-Award | A | Common Stock | 346,540 | 0.00 | — | 752,540 | — | ↗ |
| 2021-12-16 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 16,335 | 5.02 | 82.0K | 16,335 | — | ↗ |
| 2021-12-16 | Subramanian Sanjay | Officer | A-Award | A | Option(Right toBuy) | 35,560 | 5.64 | 200.6K | 71,120 | — | ↗ |
| 2021-12-16 | Potti Manish | Director | M-Exempt | A | Common Stock | 13,500 | 0.51 | 6.9K | 13,500 | — | ↗ |
| 2021-12-16 | Musunuri Shankar | Director / Officer | S-Sale | D | Common Stock | 115,000 | 5.22 | 600.3K | 1,145,299 | — | ↗ |
| 2021-12-16 | Kumar Ramesh | Director | A-Award | A | Option (Right to Buy) | 16,335 | 5.02 | 82.0K | 16,335 | — | ↗ |
| 2021-12-16 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 16,335 | 5.02 | 82.0K | 16,335 | — | ↗ |
| 2021-12-16 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 16,335 | 5.02 | 82.0K | 16,335 | — | ↗ |
| 2021-12-16 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 16,335 | 5.02 | 82.0K | 16,335 | — | ↗ |
| 2021-11-16 | Zhang Junge | Director | X-InTheMoney | A | Common Stock | 1,653 | 7.56 | 12.5K | 876,904 | — | ↗ |
| 2021-11-16 | Subramanian Sanjay | Officer | A-Award | A | Option (Right to Buy) | 35,560 | 5.64 | 200.6K | 35,560 | — | ↗ |
| 2021-11-16 | Musunuri Shankar | Director / Officer | S-Sale | D | Common Stock | 115,000 | 8.04 | 924.6K | 1,260,299 | — | ↗ |
| 2021-11-03 | Zhang Junge | Director | S-Sale | D | Common Stock | 150,300 | 17.32 | 2.60M | 731,431 | — | ↗ |
| 2021-11-02 | Zhang Junge | Director | S-Sale | D | Common Stock | 149,700 | 15.75 | 2.36M | 881,731 | — | ↗ |
| 2021-11-02 | Potti Manish | Director | S-Sale | D | Common Stock | 63,429 | 15.07 | 955.9K | 27,695 | — | ↗ |
| 2021-11-02 | Kompella Uday | Director | S-Sale | D | Common Stock | 25,000 | 16.01 | 400.3K | 154,416 | — | ↗ |
| 2021-11-02 | Castillo Kirsten | Director | S-Sale | D | Common Stock | 15,000 | 15.00 | 225.0K | 50,000 | — | ↗ |
| 2021-11-01 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 115,367 | 0.51 | 58.8K | 622,352 | — | ↗ |
| 2021-11-01 | Kompella Uday | Director | S-Sale | D | Common Stock | 25,000 | 14.05 | 351.3K | 179,416 | — | ↗ |
| 2021-10-26 | Subramanian Sanjay | Officer | S-Sale | D | Common Stock | 10,000 | 11.07 | 110.7K | 35,591 | — | ↗ |
| 2021-10-26 | Kompella Uday | Director | S-Sale | D | Common Stock | 25,000 | 12.05 | 301.3K | 204,416 | — | ↗ |
| 2021-10-25 | Kompella Uday | Director | S-Sale | D | Common Stock | 46,371 | 9.08 | 421.0K | 229,416 | — | ↗ |
| 2021-10-21 | Kompella Uday | Director | S-Sale | D | Common Stock | 1,898 | 9.01 | 17.1K | 275,787 | — | ↗ |
| 2021-10-20 | Kompella Uday | Director | S-Sale | D | Common Stock | 1,731 | 9.02 | 15.6K | 277,685 | — | ↗ |
| 2021-10-18 | Kumar Ramesh | Director | M-Exempt | A | Common Stock | 7,500 | 0.51 | 3.8K | 7,500 | — | ↗ |
| 2021-10-18 | Kompella Uday | Director | S-Sale | D | Common Stock | 200,000 | 8.41 | 1.68M | 279,416 | — | ↗ |
| 2021-10-15 | Subramanian Sanjay | Officer | M-Exempt | A | Common Stock | 7,990 | 2.19 | 17.5K | 53,581 | — | ↗ |
| 2021-10-15 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 125,000 | 0.33 | 41.3K | 1,076,587 | — | ↗ |
| 2021-09-15 | Musunuri Shankar | Director / Officer | S-Sale | D | Common Stock | 125,000 | 7.52 | 940.0K | 406,000 | — | ↗ |
| 2021-08-16 | Subramanian Sanjay | Officer | M-Exempt | A | Common Stock | 30,000 | 0.34 | 10.2K | 75,591 | — | ↗ |
| 2021-07-30 | Kompella Uday | Director | M-Exempt | A | Common Stock | 10,000 | 1.83 | 18.3K | 560,674 | — | ↗ |
| 2021-07-19 | Kumar Ramesh | Director | M-Exempt | D | Option (Right to Buy) | 7,500 | 0.51 | 3.8K | 39,000 | — | ↗ |
| 2021-07-15 | Subramanian Sanjay | Officer | M-Exempt | D | Options (Right to Buy) | 31,086 | 0.34 | 10.6K | 276,170 | — | ↗ |
| 2021-06-25 | Kompella Uday | Director | M-Exempt | A | Common Stock | 10,000 | 1.83 | 18.3K | 560,674 | — | ↗ |
| 2021-06-15 | Subramanian Sanjay | Officer | S-Sale | D | Common Stock | 31,000 | 7.00 | 217.0K | 45,591 | — | ↗ |
| 2021-06-15 | Potti Manish | Director | X-InTheMoney | D | Warrant (Right to Buy) | 95,880 | 6.30 | 604.0K | 0 | — | ↗ |
| 2021-06-08 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 22,800 | 0.33 | 7.5K | 1,326,587 | — | ↗ |
| 2021-06-07 | Musunuri Shankar | Director / Officer | M-Exempt | D | Option (Right to Buy) | 7,758 | 0.33 | 2.6K | 1,349,387 | — | ↗ |
| 2021-06-07 | Castillo Kirsten | Director | S-Sale | D | Common Stock | 10,000 | 10.00 | 100.0K | 65,000 | — | ↗ |
| 2021-05-28 | Kompella Uday | Director | S-Sale | D | Common Stock | 7,191 | 8.82 | 63.4K | 550,674 | — | ↗ |
| 2021-05-25 | Fernandes Prabhavathi | Director | M-Exempt | D | Option (Right to Buy) | 14,000 | 1.83 | 25.6K | 112,000 | — | ↗ |
| 2021-05-14 | Subramanian Sanjay | Officer | S-Sale | D | Common Stock | 31,000 | 8.18 | 253.7K | 45,591 | — | ↗ |
| 2021-05-04 | Tammara Vijay | Officer | S-Sale | D | Common Stock | 2,311 | 13.81 | 31.9K | 0 | — | ↗ |
| 2021-05-03 | Tammara Vijay | Officer | M-Exempt | D | Options (Right to Buy) | 4,317 | 0.46 | 2.0K | 4,900 | — | ↗ |
| 2021-05-03 | Potti Manish | Director | S-Sale | D | Common Stock | 60,000 | 15.02 | 901.2K | 63,429 | — | ↗ |
| 2021-05-03 | Musunuri Shankar | Director / Officer | M-Exempt | A | Common Stock | 195,809 | 0.51 | 99.9K | 601,809 | — | ↗ |
| 2021-05-03 | Kompella Uday | Director | S-Sale | D | Common Stock | 25,000 | 16.02 | 400.5K | 550,674 | — | ↗ |
| 2021-04-30 | Kompella Uday | Director | M-Exempt | D | Option (right to buy) | 20,000 | 0.51 | 10.2K | 34,000 | — | ↗ |
| 2021-04-29 | Tammara Vijay | Officer | S-Sale | D | Common Stock | 3,000 | 10.99 | 33.0K | 0 | — | ↗ |
| 2021-04-29 | Subramanian Sanjay | Officer | S-Sale | D | Common Stock | 7,990 | 10.98 | 87.7K | 45,591 | — | ↗ |
| 2021-04-26 | Kompella Uday | Director | S-Sale | D | Common Stock | 350,000 | 11.70 | 4.10M | 600,674 | — | ↗ |
| 2021-04-19 | Kumar Ramesh | Director | M-Exempt | D | Option (Right to Buy) | 7,500 | 0.51 | 3.8K | 46,500 | — | ↗ |
| 2021-03-05 | Potti Manish | Director | M-Exempt | A | Common Stock | 7,000 | 1.83 | 12.8K | 28,000 | — | ↗ |
| 2021-01-29 | Subramanian Sanjay | Officer | M-Exempt | D | Option (Right to Buy) | 35,591 | 0.51 | 18.2K | 71,183 | — | ↗ |
| 2021-01-01 | Zhang Junge | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Taspolatoglu Suha | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Tammara Vijay | Officer | A-Award | A | Option (Right to Buy) | 220,500 | 1.83 | 403.5K | 220,500 | — | ↗ |
| 2021-01-01 | Subramanian Sanjay | Officer | A-Award | A | Option (Right to Buy) | 800,000 | 1.83 | 1.46M | 800,000 | — | ↗ |
| 2021-01-01 | Potti Manish | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Musunuri Shankar | Director / Officer | A-Award | A | Option (Right to Buy) | 1,757,000 | 1.83 | 3.22M | 1,757,000 | — | ↗ |
| 2021-01-01 | Kumar Ramesh | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Kompella Uday | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2021-01-01 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 126,000 | 1.83 | 230.6K | 126,000 | — | ↗ |
| 2020-08-14 | Tammara Vijay | Officer | A-Award | A | Options (Right to Buy) | 50,000 | 0.57 | 28.3K | 50,000 | — | ↗ |
| 2020-05-28 | Castillo Kirsten | Director | P-Purchase | A | Common Stock | 75,000 | 0.31 | 23.5K | 75,000 | — | ↗ |
| 2020-05-07 | Musunuri Shankar | Director / Officer | A-Award | A | Options (Right to Buy) | 1,357,145 | 0.33 | 447.9K | 1,357,145 | — | ↗ |
| 2020-05-05 | Tammara Vijay | Officer | A-Award | A | Options (Right to Buy) | 20,573 | 0.34 | 7.0K | 20,573 | — | ↗ |
| 2020-05-05 | Subramanian Sanjay | Officer | A-Award | A | Options (Right to Buy) | 369,256 | 0.34 | 125.5K | 369,256 | — | ↗ |
| 2020-05-05 | JORGENSEN DANIEL | Officer | A-Award | A | Options (Right to Buy) | 109,913 | 0.34 | 37.4K | 109,913 | — | ↗ |
| 2020-05-05 | Beck Kelly | Officer | A-Award | A | Options (Right to Buy) | 31,916 | 0.34 | 10.9K | 31,916 | — | ↗ |
| 2020-05-05 | Arumugham Rasappa | Officer | A-Award | A | Options (Right to Buy) | 144,766 | 0.34 | 49.2K | 144,766 | — | ↗ |
| 2020-04-05 | Fernandes Prabhavathi | Director | A-Award | A | Option (Right to Buy) | 54,000 | 0.28 | 15.1K | 54,000 | — | ↗ |
| 2020-04-05 | Castillo Kirsten | Director | A-Award | A | Option (Right to Buy) | 54,000 | 0.28 | 15.1K | 54,000 | — | ↗ |
| 2020-01-02 | Zhang Junge | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | Taspolatoglu Suha | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | Tammara Vijay | Officer | A-Award | A | Options (Right to Buy) | 77,641 | 0.51 | 39.6K | 77,641 | — | ↗ |
| 2020-01-02 | Subramanian Sanjay | Officer | A-Award | A | Options (Right to Buy) | 106,774 | 0.51 | 54.5K | 106,774 | — | ↗ |
| 2020-01-02 | Potti Manish | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | Musunuri Shankar | Director / Officer | A-Award | A | Options (Right to Buy) | 933,528 | 0.51 | 476.1K | 933,528 | — | ↗ |
| 2020-01-02 | Leo Frank | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | Kumar Ramesh | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | Kompella Uday | Director | A-Award | A | Options (Right to Buy) | 54,000 | 0.51 | 27.5K | 54,000 | — | ↗ |
| 2020-01-02 | JORGENSEN DANIEL | Officer | A-Award | A | Options (Right to Buy) | 101,470 | 0.51 | 51.7K | 101,470 | — | ↗ |
| 2020-01-02 | Beck Kelly | Officer | A-Award | A | Options (Right to Buy) | 86,596 | 0.51 | 44.2K | 86,596 | — | ↗ |
| 2020-01-02 | Arumugham Rasappa | Officer | A-Award | A | Options (Right to Buy) | 111,372 | 0.51 | 56.8K | 111,372 | — | ↗ |
| 2019-12-12 | Musunuri Shankar | Director / Officer | P-Purchase | A | Common Stock | 143,000 | 0.35 | 50.1K | 406,000 | — | ↗ |
| 2019-12-11 | Musunuri Shankar | Director / Officer | P-Purchase | A | Common Stock | 263,000 | 0.41 | 107.8K | 263,000 | — | ↗ |
| 2019-12-07 | Tammara Vijay | Officer | — | D | Stock Options (right to buy) | 9,588 | 13.52 | 129.6K | 0 | — | ↗ |
| 2019-12-07 | JORGENSEN DANIEL | Officer | — | D | Stock Options (right to buy) | 9,588 | 13.52 | 129.6K | 0 | — | ↗ |
| 2019-12-07 | Beck Kelly | Officer | — | D | Stock Options (right to buy) | 9,588 | 13.52 | 129.6K | 0 | — | ↗ |
| 2019-12-07 | Arumugham Rasappa | Officer | — | D | Stock Options (right to buy) | 9,588 | 13.52 | 129.6K | 0 | — | ↗ |
| 2019-12-04 | Zhang Junge | Director | P-Purchase | A | Common Stock | 220,000 | 0.44 | 96.8K | 818,578 | — | ↗ |
| 2019-11-27 | Zhang Junge | Director | P-Purchase | A | Common Stock | 270,000 | 0.37 | 99.9K | 600,078 | — | ↗ |
| 2019-11-25 | Zhang Junge | Director | P-Purchase | A | Common Stock | 115,000 | 0.27 | 31.1K | 330,078 | — | ↗ |
| 2019-11-22 | Zhang Junge | Director | P-Purchase | A | Common Stock | 80,000 | 0.28 | 22.4K | 215,078 | — | ↗ |
| 2019-11-22 | Subramanian Sanjay | Officer | P-Purchase | A | Common Stock | 5,000 | 0.28 | 1.4K | 10,000 | — | ↗ |
| 2019-11-18 | Zhang Junge | Director | P-Purchase | A | Common Stock | 98,500 | 0.41 | 40.4K | 133,578 | — | ↗ |
| 2019-10-11 | Zhang Junge | Director | P-Purchase | A | Common Stock | 4,000 | 1.48 | 5.9K | 35,078 | — | ↗ |
| 2019-10-02 | Subramanian Sanjay | Officer | P-Purchase | A | Common Stock | 5,000 | 1.88 | 9.4K | 5,000 | — | ↗ |
| 2019-10-01 | Subramanian Sanjay | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-30 | Zhang Junge | Director | P-Purchase | A | Common Stock | 197 | 2.45 | 482.65 | 197 | — | ↗ |
| 2019-09-27 | Zhang Junge | Director | — | I | Warrants (Right to Buy) | 1,653 | 7.56 | 12.5K | 0 | — | ↗ |
| 2019-09-27 | Taspolatoglu Suha | Director | — | I | Common Stock | 0 | 0.00 | — | 742,905 | — | ↗ |
| 2019-09-27 | Tammara Vijay | Officer | — | D | Stock Options (right to buy) | 7,191 | 2.94 | 21.1K | 0 | — | ↗ |
| 2019-09-27 | Potti Manish | Director | — | I | Warrants (Right to Buy) | 95,880 | 6.30 | 604.0K | 0 | — | ↗ |
| 2019-09-27 | Musunuri Shankar | Director / Officer | — | D | Stock Option (right to buy) | 86,292 | 1.88 | 162.2K | 0 | — | ↗ |
| 2019-09-27 | Leo Frank | Director | — | D | Warrants (Right to Buy) | 1,266 | 5.05 | 6.4K | 0 | — | ↗ |
| 2019-09-27 | Kumar Ramesh | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-09-27 | Kompella Uday | Director | — | D | Warrants (Right to Buy) | 354 | 5.05 | 1.8K | 0 | — | ↗ |
| 2019-09-27 | JORGENSEN DANIEL | Officer | — | D | Stock Options (right to buy) | 2,397 | 12.18 | 29.2K | 0 | — | ↗ |
| 2019-09-27 | Beck Kelly | Officer | — | D | Stock Options (right to buy) | 11,985 | 7.56 | 90.6K | 0 | — | ↗ |
| 2019-09-27 | Arumugham Rasappa | Officer | — | D | Stock Options (right to buy) | 23,011 | 6.30 | 145.0K | 0 | — | ↗ |
| 2019-07-19 | Hood David C. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-08 | Wilmslow Estates Ltd | 10% Owner | M-Exempt | A | Common Stock | 403,845 | 0.01 | 4.0K | 4,014,415 | — | ↗ |
| 2019-02-08 | RAKIN KEVIN | Director | M-Exempt | D | Common Stock Warrant (Right to Buy) | 111,111 | 0.01 | 1.1K | 0 | — | ↗ |
| 2019-01-15 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 345,897 | 0.15 | 51.9K | 1,692,366 | — | ↗ |
| 2019-01-14 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 400,507 | 0.16 | 64.1K | 2,038,263 | — | ↗ |
| 2019-01-11 | KIRK RANDAL J | 10% Owner | S-Sale | D | Common Stock | 251,800 | 0.17 | 42.8K | 2,438,770 | — | ↗ |
| 2018-10-10 | Wilmslow Estates Ltd | 10% Owner | P-Purchase | A | Common Stock Warrant (Right to Buy) | 403,845 | 0.70 | 282.7K | 403,845 | — | ↗ |
| 2018-10-10 | RAKIN KEVIN | Director | P-Purchase | A | Common Stock Warrant (Right to Buy) | 173,076 | 0.70 | 121.2K | 173,076 | — | ↗ |
| 2018-10-10 | Lewis Michael | Director / 10% Owner | P-Purchase | A | Common Stock | 538,460 | 0.65 | 350.0K | 3,610,570 | — | ↗ |
| 2018-10-01 | Lieber Jonathan I | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 28,000 | 0.57 | 15.9K | 28,000 | — | ↗ |
| 2018-10-01 | Kennedy Stephen Richard | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 50,000 | 6.11 | 305.5K | 0 | — | ↗ |
| 2018-10-01 | Kelley Lynne E | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 200,000 | 2.21 | 442.0K | 0 | — | ↗ |
| 2018-10-01 | Haut Donald | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 105,000 | 2.63 | 276.2K | 0 | — | ↗ |
| 2018-10-01 | Gridley Adam | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 175,000 | 0.57 | 99.4K | 175,000 | — | ↗ |
| 2018-07-31 | Kelley Lynne E | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 2.21 | 442.0K | 200,000 | — | ↗ |
| 2018-06-15 | RAKIN KEVIN | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.97 | 74.3K | 25,000 | — | ↗ |
| 2018-06-15 | Lewis Michael | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.97 | 74.3K | 25,000 | — | ↗ |
| 2018-06-15 | Kong Garheng | Director | A-Award | A | Stock Option (Right to Buy) | 25,000 | 2.97 | 74.3K | 25,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-6.6K
Shares Outstanding
338.52M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Shankar Musunuri, Ph.D., MBA Chief Executive Officer, Chairman and Co-Founder | 757.9K | 385.2K | 520.5K | 269.7K | — | 8.2K | 1.94M | 40.70% | ↗ |
| 2 | 2024 | Huma Qamar, M.D., MPH, CMI Chief Medical Officer | 344.4K | 258.4K | 709.0K | 414.0K | — | — | 1.73M | 65.07% | ↗ |
| 3 | 2024 | Arun Upadhyay, Ph.D. Chief Scientific Officer | 466.2K | 169.7K | 145.7K | 75.5K | — | 13.7K | 870.9K | 25.40% | ↗ |
| 4 | 2023 | Shankar Musunuri, Ph. D., MBA Chief Executive Officer | 757.9K | 102.5K | 1.84M | 1.83M | — | 3.8K | 4.54M | 80.94% | ↗ |
| 5 | 2023 | Shankar Musunuri, Ph.D., MBA Chief Executive Officer, Chairman and Co-Founder | 757.9K | 102.5K | 1.84M | 1.83M | — | 3.8K | 4.54M | 80.94% | ↗ |
| 6 | 2023 | Arun Upadhyay, Ph.D. Chief Scientific Officer | 466.2K | 126.4K | 394.9K | 391.1K | — | 5.5K | 1.38M | 56.79% | ↗ |
| 7 | 2023 | Arun Upadhyay, Ph. D. Chief Scientific Officer | 466.2K | 126.4K | 394.9K | 391.1K | — | 5.5K | 1.38M | 56.79% | ↗ |
| 8 | 2023 | Quan Vu Former Chief Financial Officer and Chief Business Officer | 250.6K | 45.0K | 170.5K | 168.8K | — | 155.2K | 790.1K | 42.95% | ↗ |
| 9 | 2023 | Jessica Crespo, CPA Former Chief Accounting Officer and principal accounting officer | 88.7K | — | — | 305.9K | — | 317.7K | 712.3K | 42.95% | ↗ |
| 10 | 2023 | Michael Breininger, CPA, MBA, LSSBB Corporate Controller, Interim Chief Accounting Officer | — | — | — | — | — | 226.9K | 226.9K | 0.00% | ↗ |
| 11 | 2022 | Shankar Musunuri, Ph. D., MBA Chief Executive Officer | 715.0K | 474.3K | 1.64M | 4.83M | — | 12.2K | 7.66M | 84.32% | ↗ |
| 12 | 2022 | Shankar Musunuri, Ph.D., MBA Chairman of the Board and CEO | 715.0K | 474.3K | 1.64M | 4.83M | — | 12.2K | 7.66M | 84.32% | ↗ |
| 13 | 2022 | Sanjay Subramanian, MBA Former CFO, Head of Corporate Development, and Corporate Secretary | 103.9K | — | 592.5K | 3.41M | — | 82.4K | 4.19M | 95.56% | ↗ |
| 14 | 2022 | Jessica Crespo, CPA Former Chief Accounting Officer and principal accounting officer | 358.9K | 146.0K | 167.9K | 500.1K | — | 12.2K | 1.19M | 56.37% | ↗ |
| 15 | 2022 | Jessica Crespo, CPA Former Chief Accounting Officer and Senior Vice President, Finance | 358.9K | 146.0K | 167.9K | 500.1K | — | 12.2K | 1.19M | 56.37% | ↗ |
| 16 | 2021 | Shankar Musunuri, Ph.D., MBA Chairman of the Board and Chief Executive Officer | 541.3K | 292.3K | 7.30M | — | — | 11.6K | 8.14M | 89.62% | ↗ |
| 17 | 2021 | Shankar Musunuri, Ph.D., MBA Chairman of the Board and CEO | 541.3K | 292.3K | — | 7.30M | — | 11.6K | 8.14M | 89.62% | ↗ |
| 18 | 2021 | Sanjay Subramanian, MBA Former Chief Financial Officer, Head of Corporate Development, and Corporate Secretary | 385.0K | 162.6K | 2.04M | — | — | 11.6K | 2.60M | 78.51% | ↗ |
| 19 | 2021 | Sanjay Subramanian, MBA Former CFO, Head of Corporate Development, and Corporate Secretary | 385.0K | 162.6K | — | 2.04M | — | 11.6K | 2.60M | 78.51% | ↗ |
| 20 | 2021 | Vijay Tammara, Ph.D. Vice President, Regulatory Operations | 364.0K | 115.3K | 816.7K | — | — | 11.6K | 1.31M | 62.46% | ↗ |
| 21 | 2020 | Shankar Musunuri, Ph.D., MBA Chief Executive Officer | 500.0K | 269.3K | — | 771.5K | — | 11.4K | 1.55M | 49.70% | ↗ |
| 22 | 2020 | Shankar Musunuri, Ph.D., MBA Chairman of the Board and Chief Executive Officer | 500.0K | 269.3K | 771.5K | — | — | 11.4K | 1.55M | 49.70% | ↗ |
| 23 | 2020 | Sanjay Subramanian, MBA Chief Financial Officer, Head of Corporate Development and Corporate Secretary | 365.4K | 134.8K | — | 150.6K | — | 11.0K | 661.8K | 22.76% | ↗ |
| 24 | 2020 | Sanjay Subramanian, MBA Former Chief Financial Officer, Head of Corporate Development, and Corporate Secretary | 365.4K | 134.8K | 150.6K | — | — | 11.0K | 661.8K | 22.76% | ↗ |
| 25 | 2020 | Rasappa Arumugham, Ph.D. Former Chief Scientific Officer | 353.8K | 130.5K | — | 88.5K | — | 18.2K | 591.0K | 14.98% | ↗ |
| 26 | 2020 | Daniel Jorgensen, M.D., M.P.H., MBA Former Chief Medical Officer | 224.5K | — | — | 74.4K | — | 238.2K | 537.1K | 13.85% | ↗ |
| 27 | 2019 | Shankar Musunuri Chief Executive Officer | 420.0K | 141.1K | — | — | — | 11.2K | 572.3K | 0.00% | ↗ |
| 28 | 2019 | Shankar Musunuri, Ph.D., MBA Chief Executive Officer | 420.0K | 141.1K | — | — | — | 11.2K | 572.3K | 0.00% | ↗ |
| 29 | 2019 | Shankar Musunuri, Ph.D., MBA Chairman of the Board and Chief Executive Officer | 420.0K | 141.1K | — | — | — | 11.2K | 572.3K | 0.00% | ↗ |
| 30 | 2019 | Daniel Jorgensen Chief Medical Officer | 341.3K | 79.9K | — | — | — | 11.2K | 432.3K | 0.00% | ↗ |
| 31 | 2019 | Daniel Jorgensen, M.D., M.P.H., MBA Former Chief Medical Officer | 341.3K | 79.9K | — | — | — | 11.2K | 432.3K | 0.00% | ↗ |
| 32 | 2019 | Rasappa Arumugham Chief Scientific Officer | 287.0K | 67.2K | — | — | — | 11.2K | 365.4K | 0.00% | ↗ |
| 33 | 2019 | Rasappa Arumugham, Ph.D. Former Chief Scientific Officer | 287.0K | 67.2K | — | — | — | 11.2K | 365.4K | 0.00% | ↗ |
| 34 | 2018 | Adam Gridley Former President | 478.1K | — | — | 186.1K | — | — | 664.1K | 28.02% | ↗ |
| 35 | 2018 | Daniel Jorgensen Chief Medical Officer | 341.3K | — | — | 122.3K | — | 11.0K | 474.5K | 25.77% | ↗ |
| 36 | 2018 | Stephen Kennedy Former Executive Vice President and Chief Operating Officer | 391.9K | — | — | 74.2K | — | — | 466.0K | 15.91% | ↗ |
| 37 | 2018 | Shankar Musunuri Chief Executive Officer | 420.0K | — | — | — | — | 11.0K | 431.0K | 0.00% | ↗ |
| 38 | 2018 | Rasappa Arumugham Chief Scientific Officer | 285.5K | — | — | 122.3K | — | 11.0K | 418.8K | 29.20% | ↗ |
| 39 | 2018 | Donald Haut, Ph.D. Former Chief Business Officer | 377.4K | — | — | 40.4K | — | — | 417.9K | 9.68% | ↗ |
| 40 | 2017 | Adam Gridley Former President | 435.0K | 382.7K | — | 182.5K | — | — | 1.00M | 18.25% | ↗ |
| 41 | 2017 | Adam Gridley Director, President and Chief Executive Officer | 435.0K | 382.7K | — | 182.5K | — | — | 1.00M | 18.25% | ↗ |
| 42 | 2017 | Stephen Kennedy Former Executive Vice President and Chief Operating Officer | 352.9K | 240.4K | — | 138.7K | — | — | 732.1K | 18.95% | ↗ |
| 43 | 2017 | Stephen Kennedy Executive Vice President and Chief Operating Officer | 352.9K | 240.4K | — | 138.7K | — | — | 732.1K | 18.95% | ↗ |
| 44 | 2017 | Jonathan Lieber Chief Financial Officer | 335.3K | 168.4K | — | 52.2K | — | — | 555.8K | 9.38% | ↗ |
| 45 | 2017 | Donald Haut, Ph.D. Former Chief Business Officer | 213.5K | 94.3K | — | 185.0K | — | — | 492.9K | 37.53% | ↗ |
| 46 | 2016 | Adam Gridley Director, President and Chief Executive Officer | 400.4K | 218.2K | — | 166.9K | — | — | 785.6K | 21.25% | ↗ |
| 47 | 2016 | Gloria Matthews, DVM, Ph.D., DACVS Chief Medical Officer | 346.8K | 136.3K | — | 55.6K | — | — | 538.6K | 10.32% | ↗ |
| 48 | 2016 | Jonathan Lieber Chief Financial Officer | 338.8K | 140.2K | — | 39.9K | — | — | 518.8K | 7.69% | ↗ |
| 49 | 2016 | Stephen Kennedy Chief Technology Officer | 330.2K | 130.3K | — | 35.6K | — | — | 496.2K | 7.18% | ↗ |
| 50 | 2016 | Stephen Kennedy Executive Vice President and Chief Operating Officer | 330.2K | 130.3K | — | 35.6K | — | — | 496.2K | 7.18% | ↗ |
| 51 | 2015 | Adam Gridley Director, President and Chief Executive Officer | 383.8K | 77.0K | — | 832.8K | — | 15.4K | 1.31M | 63.62% | ↗ |
| 52 | 2015 | Stephen Kennedy Chief Technology Officer | 310.0K | 67.2K | — | 571.4K | — | — | 948.7K | 60.23% | ↗ |
| 53 | 2015 | Gloria Matthews, DVM, Ph.D., DACVS Chief Medical Officer | 152.6K | 47.4K | — | 466.6K | — | — | 666.6K | 69.99% | ↗ |
| 54 | 2014 | Adam Gridley Director, President and Chief Executive Officer | 224.3K | 184.0K | — | 1.56M | — | 33.1K | 1.82M | 85.86% | ↗ |
| 55 | 2014 | Adam Gridley Director, President and Chief Executive Officer | 224.3K | — | — | 1.56M | — | 33.1K | 1.82M | 85.86% | ↗ |
| 56 | 2014 | Stephen Kennedy Chief Technology Officer | 289.2K | 118.0K | — | — | — | — | 407.2K | 0.00% | ↗ |
| 57 | 2014 | Stephen Kennedy Senior Vice President of Technical Operations | 289.2K | 20.0K | — | — | — | — | 309.2K | 0.00% | ↗ |
| 58 | 2014 | Nancy Lynch, M.D. Former Chief Medical Officer | 274.3K | — | — | — | — | — | 274.3K | 0.00% | ↗ |
| 59 | 2014 | Peter Greenleaf Former Director, President and Chief Executive Officer | 68.5K | — | — | — | — | — | 68.5K | 0.00% | ↗ |
| 60 | 2014 | Patrick O’Donnell Former Chairman, President and Chief Executive Officer | — | — | — | — | — | 59.4K | 59.4K | 0.00% | ↗ |
| 61 | 2013 | Peter Greenleaf Former Director, President and Chief Executive Officer | 196.6K | — | — | 231.0K | — | 29.0K | 456.5K | 50.60% | ↗ |
| 62 | 2013 | Patrick O’Donnell Former Chairman, President and Chief Executive Officer | 46.5K | — | — | 7.1K | — | 235.9K | 289.4K | 2.45% | ↗ |
| 63 | 2013 | Stephen Kennedy Senior Vice President of Technical Operations | 116.3K | — | — | 156.0K | — | — | 272.3K | 57.28% | ↗ |
| 64 | 2013 | Nancy Lynch, M.D. Former Chief Medical Officer | 71.2K | 25.0K | — | 156.0K | — | — | 252.2K | 61.85% | ↗ |
| 65 | 2013 | Adam Gridley Director, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shankar Musunuri | Co-Founder, Chief Executive Officer & Chairman | 1M | — |
| Arun Upadhyay | Chief Scientific Officer and Head of Research & Development | 703.8K | — |
| Huma Qamar | Chief Medical Officer | 644.0K | — |
| Ramesh Ramachandran | Chief Accounting Officer & Principal Accounting Officer | 504.9K | male |
| Vijay Tammara | Chief Development Officer | 490.9K | — |
| Uday Kompella | Co-founder & Independent Director | 61.9K | — |
| Jyothy Pillai | Vice President & Head of Regulatory & Quality | — | female |
| Rita Johnson-Greene | Chief Financial Officer | — | female |
| Kristen Craft | Head of People & Culture | — | female |
| Tiffany Hamilton | AVP & Head of Corporate Communications | — | female |
| John Kouch | General Counsel | — | — |
| Paul Staid | Executive Vice President of Operations | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-11-08 | 2022-12-12 | Christopher L. Jacobs | NY27 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OCGN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
